New therapies for inflammatory bowel disease: from the bench to the bedside

被引:238
作者
Danese, Silvio [1 ]
机构
[1] Ist Clin Humanitas, Div Gastroenterol, IBD Ctr, I-20089 Milan, Italy
关键词
PLACEBO-CONTROLLED TRIAL; ACTIVE CROHNS-DISEASE; ORAL INTERLEUKIN-12/23 INHIBITOR; RECOMBINANT HUMAN INTERLEUKIN-10; ANTIINTERFERON-GAMMA ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; PHASE-I TRIAL; ULCERATIVE-COLITIS;
D O I
10.1136/gutjnl-2011-300904
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The mechanisms underlying the chronic intestinal inflammation that is a hallmark of inflammatory bowel diseases (IBD) are complex. Components of the pathological response include the adaptive and innate immune systems, as well as the intestinal epithelium and endothelium. Advances in the understanding of the roles of each of these components have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn's disease or ulcerative colitis. This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD.
引用
收藏
页码:918 / 932
页数:15
相关论文
共 140 条
[71]   Anti-interleukin-12 antibody for active Crohn's disease [J].
Mannon, PJ ;
Fuss, IJ ;
Mayer, L ;
Elson, CO ;
Sandborn, WJ ;
Present, D ;
Dolin, B ;
Goodman, N ;
Groden, C ;
Hornung, RL ;
Quezado, M ;
Neurath, MF ;
Salfeld, J ;
Veldman, GM ;
Schwertschlag, U ;
Strober, W .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (20) :2069-2079
[72]   Defective acute inflammation in Crohn's disease: a clinical investigation [J].
Marks, DJB ;
Harbord, MWN ;
MacAllister, R ;
Rahman, FZ ;
Young, J ;
Al-Lazikani, B ;
Lees, W ;
Novelli, M ;
Bloom, S ;
Segal, AW .
LANCET, 2006, 367 (9511) :668-678
[73]   Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model [J].
Matsumoto, Satoshi ;
Hara, Theko ;
Mitsuyama, Keiichi ;
Yamamoto, Mayuko ;
Tsuruta, Osamu ;
Sata, Michio ;
Scheller, Juergen ;
Rose-John, Stefan ;
Kado, Sho-ichi ;
Takada, Toshihiko .
JOURNAL OF IMMUNOLOGY, 2010, 184 (03) :1543-1551
[74]   Localized Delivery of Interferon-β by Lactobacillus Exacerbates Experimental Colitis [J].
McFarland, Adelle P. ;
Savan, Ram ;
Wagage, Sagie ;
Addison, Augustina ;
Ramakrishnan, Karthika ;
Karwan, Megan ;
Tri Duong ;
Young, Howard A. .
PLOS ONE, 2011, 6 (02)
[75]   Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis [J].
Miner, PB .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (10) :1427-1434
[76]  
Monteleone I, 2002, GUT, V50, P60
[77]   IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance [J].
Mudter, Jonas ;
Neurath, Markus F. .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (08) :1016-1023
[78]   Successful treatment of steroid refractory active ulcerative colitis with natural interferon-β -: an open long-term trial [J].
Musch, E. ;
Andus, T. ;
Malek, M. ;
Chrissafidou, A. ;
Schulz, M. .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (12) :1235-1240
[79]   Interferon-β-1a for the treatment of steroid-refractory ulcerative colitis:: A randomized, double-blind, placebo-controlled trial [J].
Musch, E ;
Andus, T ;
Kruis, W ;
Raedler, A ;
Spehlmann, M ;
Schreiber, S ;
Krakamp, B ;
Malek, M ;
Malchow, H ;
Zavada, F ;
Feurle, GE .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (06) :581-586
[80]   Induction and maintenance of clinical remission by interferon-β in patients with steroid-refractory active ulcerative colitis -: an open long-term pilot trial [J].
Musch, E ;
Andus, T ;
Malek, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) :1233-1239